What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Neurology Clinical Trials 2026: Brain Disease Research, Gene Therapy, and Patient Enrollment

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Neurological diseases — Alzheimer's, Parkinson's, ALS, multiple sclerosis, stroke, epilepsy — collectively affect more than 1 billion people worldwide and represent one of the greatest unmet medical needs in all of medicine. Clinical trials in 2026 are deploying a new generation of tools: gene therapy, antisense oligonucleotides, disease-modifying antibodies, brain stimulation devices, and GLP-1 neuroprotection strategies. This guide surveys the major trial activity, explains who qualifies, and provides a roadmap for patients and caregivers seeking to participate.

Alzheimer's Disease: Beyond Amyloid Clearance

The approval of lecanemab (Leqembi) in 2023 and donanemab (Kisunla) in 2024 marked the first disease-modifying treatments for early Alzheimer's disease — slowing cognitive decline by 27–35% in patients with early symptomatic disease and confirmed amyloid pathology. In 2026, Phase 3 trials are addressing the next questions: Can amyloid-clearing antibodies prevent dementia in cognitively unimpaired individuals with elevated amyloid (the A4 trial extension, AHEAD 3-45, TRAILBLAZER-ALZ 3)? Can subcutaneous formulations replace IV infusions? Can combination therapy (amyloid clearance plus tau-targeting) produce additive benefit?

GLP-1 agonists have emerged as a surprising neuroprotection candidate. Epidemiological data show semaglutide users have 40–70% lower rates of Alzheimer's diagnosis, Parkinson's disease, and stroke. The EVOKE trial (semaglutide vs. placebo in early Alzheimer's) and the LIRAGLUTIDE-AD2 Phase 3 are directly testing this hypothesis, with results expected by 2027. Tau-targeting approaches — ABBV-916 (anti-tau antibody), AL002 (TREM2 agonist activating microglial clearance), and small-molecule tau aggregation inhibitors — are in Phase 2 trials.

Parkinson's Disease: Gene Therapy and Alpha-Synuclein

Parkinson's disease (PD) remains without a disease-modifying therapy despite decades of research, but 2026 brings several plausible candidates into advanced trials. Alpha-synuclein — the misfolded protein that forms Lewy bodies and propagates prion-like through the brain — is targeted by BIIB054 (cinpanemab), PRX002 (prasinezumab), and PASADENA Phase 2 trials. While early passive immunization trials were disappointing, active immunization (UB-312 vaccine, AFFiRiS) and antisense oligonucleotides targeting SNCA mRNA are entering clinical evaluation.

Gene therapy for PD is most advanced for monogenic forms: LRRK2 mutations (BIIB094 antisense oligonucleotide in Phase 1/2 REASON trial), GBA mutations (LY3884961 chaperone, venglustat in Phase 2), and AAV-based gene replacement. GDNF gene therapy (Asklepios AGTC-110) delivered via convection-enhanced MRI-guided injection into the putamen is in Phase 2, attempting to restore dopaminergic neuron survival. Focused ultrasound (FUS) for essential tremor and PD tremor has achieved FDA approval for essential tremor, with the SONIFICATION Phase 3 now evaluating bilateral FUS thalamotomy for PD tremor.

ALS: Antisense Oligonucleotides and the Biomarker Era

Amyotrophic lateral sclerosis (ALS) research has been transformed by the approval of tofersen (Qalsody) for SOD1-ALS — the first drug to slow disease progression in a genetically defined ALS subset — and by the ATLAS presymptomatic trial, which is intervening with tofersen in SOD1 variant carriers before symptom onset, guided by plasma neurofilament light (NfL) biomarker elevation. This represents the first presymptomatic ALS trial, a conceptual breakthrough analogous to the Alzheimer's prevention trials.

The HEALEY ALS Platform Trial at Massachusetts General Hospital is a perpetual master protocol running multiple treatments simultaneously using a shared control arm — an efficient design that accelerates ALS drug evaluation. Treatments in current HEALEY arms include zilucoplan (complement C5 inhibitor), CNM-Au8 (gold nanocrystal neuronal energy support), and reldesemtiv (fast-skeletal troponin activator). RNA-targeting approaches for C9orf72 ALS (the most common genetic form) and FUS-ALS are in Phase 1/2.

Multiple Sclerosis: BTK Inhibitors and Progressive Disease

Multiple sclerosis (MS) has a robust armamentarium for relapsing forms but remains without meaningful treatment for progressive MS, affecting ~15% of patients. Bruton's tyrosine kinase (BTK) inhibitors — tolebrutinib (Sanofi), evobrutinib (Merck), fenebrutinib (Roche) — are in Phase 3 for both relapsing and progressive MS, acting on CNS-resident B cells and microglia in ways that existing treatments (which primarily reduce peripheral immune trafficking) cannot. Tolebrutinib's HERCULES Phase 3 for non-relapsing secondary progressive MS (POMS) showed a significant delay in disability worsening — an unprecedented result in this population.

Remyelination — restoring the myelin sheath that MS destroys — is addressed by opicinumab (anti-LINGO-1 antibody, Biogen), MD1003 (high-dose biotin), and clemastine (antihistamine repurposed for remyelination based on Columbia University discovery). These trials are enrolling patients with stable MS who have residual deficits from prior relapses, measuring remyelination via visual evoked potentials and MRI magnetization transfer ratio.

Stroke Recovery and Neuroprotection

Stroke clinical trials in 2026 focus on three areas: extending the time window for thrombolysis, neuroprotection in the acute phase, and rehabilitation enhancement in the recovery phase. Tenecteplase is replacing alteplase as the preferred thrombolytic following the AcT and NOR-TEST trials showing non-inferiority with easier single-bolus dosing. The TIMELESS trial is testing tenecteplase beyond 4.5 hours using perfusion imaging to select patients with salvageable tissue. The FRONTIER trial is testing nerinetide (NA-1, a PSD-95 neuroprotection peptide) as a bridge between stroke onset and hospital arrival.

Brain stimulation for stroke recovery — transcranial direct current stimulation (tDCS), repetitive TMS (rTMS), and epidural cortical stimulation — are in Phase 2/3 for upper limb motor recovery (EVEREST-2, NICHE Phase 3). Combined brain stimulation plus intensive physical therapy protocols show synergistic effects on motor cortex plasticity. STEM20 and BrainSTAR are evaluating stem cell therapies (modified mesenchymal stem cells) for subacute and chronic stroke motor deficits.

Key Takeaways

Alzheimer's prevention trials (AHEAD 3-45, TRAILBLAZER-ALZ 3) are enrolling cognitively unimpaired adults with elevated amyloid to test whether intervening before symptoms appear can prevent dementia — the most important question in Alzheimer's research.
The ATLAS trial for presymptomatic SOD1-ALS, guided by plasma NfL biomarker, is a historic first in ALS — treating before symptom onset using a proven biomarker to identify the right timing for intervention.
BTK inhibitors (tolebrutinib HERCULES) showed significant delay in disability worsening in non-relapsing secondary progressive MS — the first drug class with meaningful Phase 3 results in this underserved population.
GLP-1 agonists are in Phase 3 neurology trials (EVOKE, LIRAGLUTIDE-AD2) for Alzheimer's based on epidemiological data showing 40–70% lower rates of neurodegeneration in GLP-1 users.
The HEALEY ALS Platform Trial, Alzheimer's master protocols, and MS sequential trial networks demonstrate how platform trial designs are accelerating neurological drug development by testing multiple agents simultaneously against shared controls.